Article in Journal of the American Heart Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
19 authors.
Alban TodescoDepartment of Thoracic Surgery, Diseases of the Esophagus and Lung Transplantation, North Hospital Aix Marseille University, Assistance Publique-Hôpitaux de Marseille Marseille France.
Julien GrynblatINSERM UMR_S 999 Pulmonary Hypertension: Pathophysiology and Novel Therapies Le Plessis Robinson France.ORCID 0000-0001-5593-3383
Kouamé Kan Firmin AkoumiaINSERM UMR_S 999 Pulmonary Hypertension: Pathophysiology and Novel Therapies Le Plessis Robinson France.ORCID 0009-0000-8248-9628
Damien BonnetM3C-Necker, Hôpital Necker-Enfants malades AP-HP Université de Paris Cité, Cardiologie Congénitale et Pédiatrique Paris France.ORCID 0000-0002-8722-5805
Pedro Mendes-FerreiraCardiovascular R&D Centre, UnIC@RISE, Department of Surgery and Physiology Faculty of Medicine of the University of Porto Porto Portugal.ORCID 0000-0003-3616-6785
Denis ChemlaINSERM UMR_S 999 Pulmonary Hypertension: Pathophysiology and Novel Therapies Le Plessis Robinson France.ORCID 0000-0001-7479-9896
Marilyne LevyM3C-Necker, Hôpital Necker-Enfants malades AP-HP Université de Paris Cité, Cardiologie Congénitale et Pédiatrique Paris France.ORCID 0000-0003-2202-273X
Mathilde MéotM3C-Necker, Hôpital Necker-Enfants malades AP-HP Université de Paris Cité, Cardiologie Congénitale et Pédiatrique Paris France.ORCID 0000-0001-9306-5580
Sophie-Guiti Malekzadeh-MilaniM3C-Necker, Hôpital Necker-Enfants malades AP-HP Université de Paris Cité, Cardiologie Congénitale et Pédiatrique Paris France.ORCID 0000-0002-9527-3671
Birger TielemansDepartment of Imaging and Pathology, Biomedical MRI unit/Mosaic KU Leuven Leuven Belgium.ORCID 0000-0002-1775-1797
Benoit DecantePreclinical Research Laboratory, Pulmonary Hypertension National Referral Center, Hôpital Marie Lannelongue, Groupe Hospitalier Paris Saint Joseph Paris-Saclay University Le Plessis Robinson France.ORCID 0000-0003-1642-7589
Carine Vastel-AmzallagPaediatric Cardiology, Centre de Spécialités Pédiatriques de l'Est Parisien, CSPEP Créteil France.
Paul HabertDepartment of Radiology North Hospital, Assistance Publique-Hôpitaux de Marseille Marseille France.ORCID 0000-0003-2510-2727
Maria-Rosa GhignaINSERM UMR_S 999 Pulmonary Hypertension: Pathophysiology and Novel Therapies Le Plessis Robinson France.ORCID 0000-0001-5996-665X
Marc HumbertINSERM UMR_S 999 Pulmonary Hypertension: Pathophysiology and Novel Therapies Le Plessis Robinson France.ORCID 0000-0003-0703-2892
David MontaniINSERM UMR_S 999 Pulmonary Hypertension: Pathophysiology and Novel Therapies Le Plessis Robinson France.ORCID 0000-0002-9358-6922
David BoulateDepartment of Thoracic Surgery, Diseases of the Esophagus and Lung Transplantation, North Hospital Aix Marseille University, Assistance Publique-Hôpitaux de Marseille Marseille France.ORCID 0000-0003-4757-4565
Frédéric PerrosINSERM UMR_S 999 Pulmonary Hypertension: Pathophysiology and Novel Therapies Le Plessis Robinson France.ORCID 0000-0001-7730-2427
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
backgroundThe primary genetic risk factor for heritable pulmonary arterial hypertension is the presence of monoallelic mutations in the METHODS AND
resultsMale and female rats with a 71 bp monoallelic deletion in exon 1 of
conclusionsOur novel 2-hit rat model presents a promising avenue to explore the adaptation of the right ventricle and pulmonary vasculature to PH, shedding light on pertinent sex- and gene-related effects.
Indexed as
Bone Morphogenetic Protein Receptors, Type IIDisease Models, AnimalHemodynamicsMutationPulmonary ArteryAnimalsArterial PressureFemaleHypertension, PulmonaryMaleMyocardial ContractionPulmonary Arterial HypertensionRatsRats, Sprague-DawleyStenosis, Pulmonary ArteryVascular RemodelingBmpr2 protein, ratBone Morphogenetic Protein Receptors, Type IIbone morphogenetic protein receptor type 2pulmonary arterial hypertensionpulmonary artery occlusionpulmonary hypertension
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Pulmonary Hypertension Induced by Right Pulmonary Artery Occlusion: Hemodynamic Consequences of · full record | OpenQuestion